World Antibody-Drug Conjugate Market Discussed by DelveInsight in New Research Report Published at MarketPublishers.com
31 Mar 2015 • by Natalie Aster
LONDON – Antibody-drug conjugates (ADCs) are monoclonal antibodies attached to biologically active cytotoxic (anticancer) drugs by chemical, stable linkers with labile bonds. The continuous research on this therapy is expected to substitute the chemotherapy options in the short run and thus reduce their toxic side-effects. Billions of dollars are spent all over the world on the chemotherapy medications on a yearly basis. Various companies in in the biotech and pharma business are cooperating in all areas of ADCs such as antibody production, linker technology and the process of conjugation. Seattle Genetics’ brentuximab vedotin (BV) and Roche’s trastuzumab emtansine are the only ADCs that have received market approval; their combined sales reached the USD 523 million mark as of 2013. All in all, there are 264 pipeline ADCs, with 253 ADCS being developed just for oncology indications. Pipeline is very rich with 4 potential drugs in Phase III studies, out of which Adcetris and Kadcyla are undergoing clinical trials for various disorders. Geography-wise, North America boasts of having the largest number of ADCs in clinical trials, with 161 ADCs and 65 active companies, followed by the European region with 38 active firms and 81 products as well as APAC with 18 ADCs currently undergoing studies.
New report “Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015” elaborated by DelveInsight gives an all-encompassing analysis of the world’s antibody-drug conjugate market landscape. It identifies key market trends, driving forces and restraints; reviews marketed ADC products and their marketing status; covers major ADC therapies under development from pole to pole. The research report examines the competitive landscape of test drugs for top players and leading therapy areas; offers a description of the products, development phase, collaborators and licensors, core information on development partners and technologies; limelights the pre-clinical and clinical therapy outcomes; gives insights into the targets and detailed MoA; highlights the licensing opportunities and details on therapy funding; as well as provides access to information on discontinued and dormant pipeline projects.
Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2015
Published: March, 2015
Price: US$ 3,500.00
More new studies by the publisher can be found at DelveInsight page.